Fig. 5: ARAC elicits anti-tumor immune effects.
From: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
a 100,000 LLC-JSP cells were injected in right flank and 40,000 cells were injected in left flank of C57BL/6 mice. On day 12 post tumor inoculation, mice (n = 7 per treatment group) received intratumoral treatments of saline, p-NP, iPLK1-NP, or ARAC to the right (local) tumor. Each dose consists of 0.5 mg NP (containing 2.5 µg volasertib and/or 20 µg PD-L1 antibody) in 50 µl per dose for 3 doses total. b Local (treated) tumor growth. Data presented as mean ± SEM; *P = 0.0104, **P = 0.0017, ****P < 0.0001 (Two-Way repeated measures ANOVA with Tukey’s correction for multiple comparisons). c Distant (untreated) tumor growth of individual mice (distant tumors developed in 6/7 saline, 3/7 p-NP, 3/7 iPLK1-NP, and 2/7 ARAC at shown time-points). d Kaplan–Meier Survival curve (mice were euthanized when a combined tumor size reached 2000 mm3). **P = 0.0036 for ARAC vs. saline (Log-rank Mantel–Cox test). e–g Mice (n = 7) were inoculated with 250,000 and 100,000 LLC-JSP cells for bilateral tumors and treated as shown in (a) with ARAC or saline. One day post 3rd injection, tumors were harvested and processed into single cell suspensions for flow cytometry analysis. e PD-L1 expression (median fluorescent intensity; MFI) in CD45+ and CD45− cells. f Proliferative effector T cells (%Ki67 of CD44+ CD8+ cells) in tumor-draining lymph nodes. g CD45+ (% of live cells), CD8+ (% of CD45+ CD3+ cells), CD4+ (% of CD45+ CD3+ cells), and CD8+/Treg (Regulatory T cells; CD4+ FoxP3+ (% of CD45+ CD3+ cells)) in tumors. Data presented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001 (One-Way ANOVA with Tukey’s correction for multiple comparisons). Source data are provided as a Source Data file.
